NCT07689682 OPM- MEG in Non-immune And iMmune-medIated Neurological Disease
| NCT ID | NCT07689682 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Aston University |
| Condition | Autoimmune Encephalitis (AE) |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2026-05-15 |
| Primary Completion | 2034-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2026-05-15 with a primary completion date of 2034-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Over the past 20 years, doctors have gotten much better at spotting and treating brain conditions caused by the immune system attacking the body. These include illnesses like autoimmune encephalitis, ADEM, and multiple sclerosis. But even with better treatments, many patients-especially children-still struggle with long-term problems. Standard brain scans and tests often miss important issues like memory problems, emotional difficulties, trouble sleeping, and challenges with social behaviour. Early research using a special brain imaging technique (called MEG) has shown changes in brain networks that seem to be linked to poor memory. This study will use a new, advanced version of MEG that works even with very young children (as young as 2 years old). The goal is to better understand how these brain conditions affect children, compare them with other types of brain illness, and eventually use this technology to help predict outcomes and discover new ways to track brain health.
Eligibility Criteria
Inclusion Criteria: * Individuals (age range 2 yrs to 16 years) who have received a diagnosis of immune-mediated neurological disease e.g. autoimmune encephalitis1, acute disseminated encephalomyelitis, multiple sclerosis. 2 * Individuals who have received a diagnosis of a non-immune mediated neurological disease (age range 2 yrs to 15 years 11 months) e.g. stroke. * Patients who can give informed consent/ assent and have a person with parental responsibility capable of giving informed consent on their behalf if aged \<16 years. Exclusion Criteria: * There is metal in the body or any other contraindication that precludes MRI scanning at IHN, or child usually requires sedation for clinical MRI scans. * Participant dissents.
Contact & Investigator
Sukhvir Wright
PRINCIPAL INVESTIGATOR
Aston University
Frequently Asked Questions
Who can join the NCT07689682 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 16 Years, studying Autoimmune Encephalitis (AE). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07689682 currently recruiting?
Yes, NCT07689682 is actively recruiting participants. Contact the research team at omegamind@aston.ac.uk for enrollment information.
Where is the NCT07689682 trial being conducted?
This trial is being conducted at Birmingham, United Kingdom, Birmingham, United Kingdom.
Who is sponsoring the NCT07689682 clinical trial?
NCT07689682 is sponsored by Aston University. The principal investigator is Sukhvir Wright at Aston University. The trial plans to enroll 90 participants.